Retrospective Analysis of the Effect of Uric Acid on the Prognosis of Immunoglobulin A Nephropathy With Stage 3-4 Chronic Kidney Disease

YU Zixian, QIN Yunlong, YUAN Jinguo, ZHAO Jin, SUN Shiren

Abstract

To investigate the effect of uric acid on the clinicopathological characteristics and prognosis of immunoglobulin A nephropathy (IgAN) in patients with stage 3-4 chronic kidney disease (CKD).   Methods  The clinical and pathological data of 263 IgAN patients who had stage 3-4 CKD and who had confrimed diagosis through renal biopsy at the First Affiliated Hospital of Air Force Medical University between December 2008 and January 2020 were retrospectively collected. According to the levels of uric acid, the patients were divided into a hyperuricemia group (n=102) and a normal uric acid group (n=161), and the clinicopathological characteristics of the two groups were compared accordingly. With progression to end-stage renal disease or death as the endpoint event, the renal survival rate of the two groups was compared by the Kaplan-Meier method and the relationship between uric acid and the prognosis was analyzed by Cox regression and LASSO regression.   Results  Compared with the normal uric acid group, the hyperuricemia group had a significantly higher proportion of male patients and patients with a history of hypertension, a significantly higher level of blood urea nitrogen, and lower levels of estimated glomerular filtration rate and high-density lipoprotein. In terms of pathology, patients in the hyperuricemia group had significantly higher proportion of glomerulosclerosis, higher mesangial hypercellularity, and higher tubular atrophy/interstitial fibrosis (P<0.05). Kaplan-Meier curve showed that there was a significant difference in renal survival rate between the two groups (P<0.0001). LASSO regression showed that high uric acid was a risk factor for the prognosis of IgAN patients with stage 3-4 CKD. Further multivariate Cox analysis showed that, compared with the normal uric acid group, the hyperuricemia group had a higher risk of incurring composite outcomes (hazard ratio [HR]=1.61, 95% confidence interval [CI]: 1.10-2.34). When uric acid was used as a continuous variable, the increase of 1 mg/dL in uric acid concentration was associated with an increased HR of 1.18 (95% CI: 1.08-1.29) for the composite outcome.   Conclusion  High uric acid is a risk factor for poor renal prognosis in IgAN patients with stage 3-4 CKD and reducing uric acid levels may effectively improve the prognosis of high-risk IgAN patients.

 

Keywords: IgA nephropathy,  Chronic kidney disease,  Hyperuricemia,  Prognosis,  Retrospective

 

Full Text:

PDF


References


Kidney Disease: Improving Global Outcomes Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the management of glomerular diseases. Kidney Int，2021，100(4S): S1–S276. doi: 10.1016/j. kint.2021.05.021.

BARBOUR S J， COPPO R， ZHANG H， et al. Evaluating a new international risk-prediction tool in IgA nephropathy. JAMA Intern Med，2019，179(7): 942–952. doi: 10.1001/jamainternmed.2019.0600.

RODRIGUES J C， HAAS M， REICH H N. IgA nephropathy. Clin J Am Soc Nephrol，2017，12(4): 677–686. doi: 10.2215/CJN.07420716.

JIA Q， MA F， ZHAO J， et al. Effect of corticosteroids combined with cyclophosphamide or mycophenolate mofetil therapy for IgA nephropathy with stage 3 or 4 chronic kidney disease: a retrospective cohort study. Front Pharmacol，2022，13: 946165. doi: 10.3389/fphar. 2022.946165.

ZHAO J， MA F， BAI M. Low-dose corticosteroid combined with mycophenolate mofetil for IgA nephropathy with stage 3 or 4 CKD: a retrospective cohort study. Clin Ther，2021，43(5): 859–870. doi: 10.1016/j.clinthera.2021.03.009.

Hyperuricemia, acute and chronic kidney disease, hypertension, and cardiovascular disease: report of a scientific workshop organized by the national kidney foundation. Am J Kidney Dis，2018，71(6): 851–865. doi: 10.1053/j.ajkd. 2017.12.009.

SHARAF EL DIN U A A， SALEM M M， ABDULAZIM D O. Uric acid in the pathogenesis of metabolic, renal, and cardiovascular diseases: a review. J Adv Res，2017，8(5): 537–548. doi: 10.1016/j.jare.2016.11.004.

ZHANG K， TANG L， JIANG S S， et al. Is hyperuricemia an independent prognostic factor for IgA nephropathy: a systematic review and meta-analysis of observational cohort studies. Renal Failure，2022， 44(1): 70–80. doi: 10.1080/0886022X.2021.2019589.

GOLDBERG A， GARCIA-ARROYO F， SASAI F， et al. Mini review: reappraisal of uric acid in chronic kidney disease. Am J Nephrol，2021， 52(10−11): 837–844. doi: 10.1159/000519491.

BADVE S V， PASCOE E M， TIKU A， et al. Effects of allopurinol on the progression of chronic kidney disease. N Engl J Med，2020，382(26): 2504–2513. doi: 10.1056/NEJMoa1915833.

KIMURA K， HOSOYA T， UCHIDA S， et al. Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: a randomized trial. Am J Kidney Dis，2018，72(6): 798–810. doi: 10.1053/j. ajkd.2018.06.028.

TRIMARCHI H， BARRATT J， CATTRAN D C， et al. Oxford classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. Kidney Int，2017，91(5): 1014–1021. doi: 10.1016/j.kint.2017.02.003.

INKER L A， ENEANYA N D， CORESH J， et al. New creatinine- and cystatin C-based equations to estimate GFR without race. N Engl J Med， 2021，385(19): 1737–1749. doi: 10.1056/NEJMoa2102953.

LE W， LIANG S， HU Y， et al. Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population. Nephrol Dial Transplant，2012， 27(4): 1479–1485. doi: 10.1093/ndt/gfr527.

LV J， ZHANG H， ZHOU Y， et al. Natural history of immunoglobulin A nephropathy and predictive factors of prognosis: a long-term follow up of 204 cases in China. Nephrology (Carlton)，2008，13(3): 242–246. doi: 10. 1111/j.1440-1797.2007.00898.x.

WU Y Y， QIU X H， YE Y， et al. Risk factors analysis for hyperuricemic nephropathy among CKD stages 3-4 patients: an epidemiological study of hyperuricemia in CKD stages 3-4 patients in Ningbo, China. Ren Fail， 2018，40(1): 666–671. doi: 10.1080/0886022X.2018.1487859.

GRAYSON P C， KIM S Y， LAVALLEY M， et al. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthrit Care Res，2011，63(1): 102–110. doi: 10.1002/acr.20344.

SYRJANEN J， MUSTONEN J， PASTERNACK A. Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy. Nephrol Dial Transplant，2000，15(1): 34–42. doi: 10.1093/ndt/15.1.34.

GENG Y H， ZHANG Z， ZHANG J J， et al. Hyperuricemia aggravates the progression of IgA nephropathy. Int Urol Nephrol，2022，54(9): 2227–2237. doi: 10.1007/s11255-022-03125-4.

MORIYAMA T， ITABASHI M， TAKEI T， et al. High uric acid level is a risk factor for progression of IgA nephropathy with chronic kidney disease stage G3a. J Nephrol，2015，28(4): 451–456. doi: 10.1007/s40620-014-0154-0.

SRIVASTAVA A， KAZE A D， MCMULLAN C J， et al. Uric acid and the risks of kidney failure and death in individuals with CKD. Am J Kidney Dis，2018，71(3): 362–370. doi: 10.1053/j.ajkd.2017.08.017.

SIRCAR D， CHATTERJEE S， WAIKHOM R， et al. Efficacy of febuxostat for slowing the GFR decline in patients with CKD and asymptomatic hyperuricemia: a 6-month, double-blind, randomized, placebo-controlled trial. Am J Kidney Dis，2015，66(6): 945–950. doi: 10. 1053/j.ajkd.2015.05.017.


Refbacks

  • There are currently no refbacks.